Sunesis Pharmaceuticals (SNSS) Getting Somewhat Positive Media Coverage, Analysis Shows
News articles about Sunesis Pharmaceuticals (NASDAQ:SNSS) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sunesis Pharmaceuticals earned a news impact score of 0.10 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.460057121633 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Sunesis Pharmaceuticals (SNSS) traded up 1.52% on Thursday, hitting $2.00. 40,445 shares of the stock were exchanged. Sunesis Pharmaceuticals has a 52-week low of $1.84 and a 52-week high of $4.53. The stock’s market cap is $47.03 million. The company’s 50 day moving average is $2.14 and its 200-day moving average is $2.74.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.35. During the same quarter last year, the firm posted ($0.12) earnings per share. Analysts predict that Sunesis Pharmaceuticals will post ($1.61) EPS for the current fiscal year.
Several equities research analysts have recently commented on SNSS shares. Zacks Investment Research upgraded shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price target for the company in a report on Thursday, August 24th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $3.00 price objective on shares of Sunesis Pharmaceuticals in a research report on Wednesday, September 27th. Finally, ValuEngine downgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
WARNING: “Sunesis Pharmaceuticals (SNSS) Getting Somewhat Positive Media Coverage, Analysis Shows” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/sunesis-pharmaceuticals-snss-getting-somewhat-positive-media-coverage-analysis-shows/1642029.html.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.